<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02040597</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-05993AA1-10</org_study_id>
    <secondary_id>2013-002140-91</secondary_id>
    <nct_id>NCT02040597</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.</brief_title>
  <acronym>TRIPLE10</acronym>
  <official_title>Open-label, Non-randomized, Parallel-group Study to Investigate the Pharmacokinetics, Safety and Tolerability of a Single Dose of CHF 5993 pMDI in Subjects With Mild, Moderate and Severe Renal Impairment in Comparison With Matched Healthy Control Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is performed to characterize the pharmacokinetics of glycopyrrolate bromide after
      single administration of CHF 5993 pressurised Metered Dose Inhaler (pMDI) in subjects with
      different level of renal impairment in comparison with matching healthy volunteers. Moreover,
      the safety and tolerability of the study drug will be also evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycopyrrolate area under the curve (AUC)</measure>
    <time_frame>over 72 h after single administration</time_frame>
    <description>AUC until the last quantifiable concentration (AUCt)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycopyrrolate other Pharmacokinetic parameters in plasma</measure>
    <time_frame>Over 72 h after single administration</time_frame>
    <description>AUC until 72 h post dose (AUC0-72h), AUC extrapolated to infinity (AUCinf), maximum plasma concentratio (Cmax), time to maximum plasma concentration (tmax), half-life, clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B17MP and Formoterol pharmacokinetic parameters in plasma</measure>
    <time_frame>over 24 h after single administration</time_frame>
    <description>AUCt, AUC until 24 h post dose (AUC0-24h), AUCinf, Cmax, tmax, half-life, clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDP pharmacokinetic parameters in plasma</measure>
    <time_frame>over 24 h after single administration</time_frame>
    <description>AUCt, AUCinf, Cmax, tmax, half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Glycopyrrolate excretion (Ae)</measure>
    <time_frame>over 72 h after single administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine formoterol excretion (Ae)</measure>
    <time_frame>Over 24 h after single administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>A period of 3 to 7 weeks (from screening visit to follow-up phone call)</time_frame>
    <description>This includes a period of 3 to 7 weeks (depending on duration of screening and follow-up periods), before and after the study drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>over 24 h after single administration</time_frame>
    <description>systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (ECG) parameters</measure>
    <time_frame>over 24 h after single administration</time_frame>
    <description>Heart rate (HR), time interval between ECG waves Q and T corrected for heart rate with Fridericia's formula (QTcF), time interval between the onset of the ECG wave P and the start of the QRS complex (PR), time interval between the beginning of Q wave and the termination of the S wave (QRS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>CHF5993 pMDI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF 5993 pMDI (Beclometasone/Formoterol/Glycopyrrolate 100/6/25 mcg) 4 inhalations</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beclometasone/Formoterol/Glycopyrrolate</intervention_name>
    <arm_group_label>CHF5993 pMDI</arm_group_label>
    <other_name>CHF 5993 pMDI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers and

          -  Subjects with mild, moderate and severe renal impairment

        Exclusion Criteria:

          -  pregnant or lactating women

          -  positive HIV and hepatitis serology

          -  history of drug abuse

          -  history of hypersensitivity to the products used in the trial

          -  smokers

          -  respiratory disease such as asthma and COPD

          -  clinically relevant concomitant disease that may introduce a risk for the
             subjects'safety

          -  presence of kidney stones

          -  dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Kuna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University in Lodz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kasia Jarus-Dziedzic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biovirtus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biovirtus Research Site</name>
      <address>
        <city>Nadarzyn</city>
        <state>Mokra 7</state>
        <zip>05-830</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University in Lodz</name>
      <address>
        <city>Lodz</city>
        <state>ul. Kopci≈Ñskiego 22</state>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2014</study_first_submitted>
  <study_first_submitted_qc>January 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2014</study_first_posted>
  <last_update_submitted>July 30, 2015</last_update_submitted>
  <last_update_submitted_qc>July 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

